EGFL7: A unique angiogenic signaling factor in vascular development and disease

Blood

Volumn 119, Issue 6, 2012, Pages 1345-1352

  Nichol, Donna ^a   Stuhlmann, Heidi ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CHEMOATTRACTANT; EPIDERMAL GROWTH FACTOR LIKE DOMAIN 7; NOTCH RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; BLOOD VESSEL INJURY; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENE STRUCTURE; GLIOBLASTOMA; HUMAN; HYPOXIA; IN VIVO STUDY; KIDNEY TUMOR; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SURGERY; ZEBRA FISH;

EID: 84856837903     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-322446     Document Type: Review

References (61)

1. Chappell JC, Bautch VL. Vascular development: genetic mechanisms and links to vascular disease. Curr Top Dev Biol. 2010;90:43-72.
2. Herbert SP, Stainier DYR. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol. 2011; 12(9):551-564.
3. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161(6):1163-1177. (Pubitemid 36870177)
4. Davis GE, Stratman AN, Sacharidou A, Koh W. Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting. Int Rev Cell Mol Biol. 2011; 288:101-165.
5. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389-395. (Pubitemid 30208155)
6. Ribatti D, Nico B, Crivellato E. Morphological and molecular aspects of physiological vascular morphogenesis. Angiogenesis. 2009;12(2):101-111.
7. Gridley T. Notch signaling in the vasculature. Curr Top Dev Biol. 2010;92:277-309.
8. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell. 2009;16(2):196-208.
9. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15(2):272-284.
10. Wang S, Aurora AB, Johnson BA, et al. The endothelial- specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008; 15(2):261-271.
11. Kuhnert F, Mancuso MR, Hampton J, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development. 2008;135(24):3989-3993.
12. Fitch MJ, Campagnolo L, Kuhnert F, Stuhlmann H. Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn. 2004;230(2):316-324. (Pubitemid 38669592)
13. Parker LH, Schmidt M, Jin SW, et al. The endothelial- cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature. 2004;428(6984): 754-758. (Pubitemid 38514720)
14. Soncin F, Mattot V, Lionneton F, et al. VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J. 2003;22(21):5700-5711. (Pubitemid 37408810)
15. Campagnolo L, Leahy A, Chitnis S, et al. EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J Pathol. 2005;167(1):275-284. (Pubitemid 40884788)
16. Nichol D, Shawber C, Fitch MJ, et al. Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. Blood. 2010; 116(26):6133-6143.
17. Schmidt M, Paes K, De Maziere A, et al. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development. 2007;134(16):2913-2923. (Pubitemid 47386904)
18. De Val S, Chi NC, Meadows SM, et al. Combinatorial regulation of endothelial gene expression by ets and forkhead transcription factors. Cell. 2008; 135(6):1053-1064.
19. Le Bras A, Samson C, Trentini M, et al. VE-statin/ egfl7 expression in endothelial cells is regulated by a distal enhancer and a proximal promoter under the direct control of Erg and GATA-2. PLoS One. 2010;5(8):e12156.
20. Donaldson IJ, Chapman M, Kinston S, et al. Genome-wide identification of cis-regulatory sequences controlling blood and endothelial development. Hum Mol Genet. 2005;14(5):595-601. (Pubitemid 40309585)
21. Doliana R, Bot S, Bonaldo P, Colombatti A. EMI, a novel cysteine-rich domain of EMILINs and other extracellular proteins, interacts with the gC1q domains and participates in multimerization. FEBS Lett. 2000;484(2):164-168.
22. Engel J. Egf-like domains in extracellular-matrix proteins: localized signals for growth and differentiation. FEBS Lett. 1989;251(1-2):1-7. (Pubitemid 19181841)
23. Lindsell CE, Shawber CJ, Boulter J, Weinmaster G. Jagged: a mammalian ligand that activates Notch1. Cell. 1995;80:909-917.
24. Campagnolo L, Moscatelli I, Pellegrini M, Siracusa G, Stuhlmann H. Expression of EGFL7 in primordial germ cells and in adult ovaries and testes. Gene Expr Patterns. 2008;8(6):389-396.
25. Schmidt MH, Bicker F, Nikolic I, et al. Epidermal growth factor-like domain 7 (EGFL7) modulates Notch signalling and affects neural stem cell renewal. Nat Cell Biol. 2009;11(7):873-880.
26. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130(4):691-703. (Pubitemid 47268059)
27. Drake CJ, Fleming PA. Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood. 2000;95(5): 1671-1679. (Pubitemid 30120828)
28. Yamaguchi TP, Dumont DJ, Conlon RA, Breitman ML, Rossant J. flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development. 1993; 118(2):489-498. (Pubitemid 23214035)
29. Lelievre E, Hinek A, Lupu F, Buquet C, Soncin F, Mattot V. VE-statin/egfl7 regulates vascular elastogenesis by interacting with lysyl oxidases. EMBO J. 2008;27(12):1658-1670.
30. Durrans A, Stuhlmann H. A role for Egfl7 during endothelial organization in the embryoid body model system. J Angiogenes Res. 2010;2(4):1-12.
31. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006;126(4):677-689. (Pubitemid 44233625)
32. De Maziere A, Parker L, Van Dijk S, Ye W, Klumperman J. Egfl7 knockdown causes defects in the extension and junctional arrangements of endothelial cells during zebrafish vasculogenesis. Dev Dyn. 2008;237(3):580-591. (Pubitemid 351398025)
33. Badiwala MV, Tumiati LC, Joseph JM, et al. Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia/reoxygenation injury in human coronary artery endothelial cells. Circulation. 2010;122(11 suppl):S156-S161.
34. Gustavsson M, Mallard C, Vannucci SJ, Wilson MA, Johnston MV, Hagberg H. Vascular response to hypoxic preconditioning in the immature brain. J Cereb Blood Flow Metab. 2007; 27(5):928-938. (Pubitemid 46659031)
35. Badiwala MV, Guha D, Tumiati L, et al. Epidermal growth factor-like domain 7 is a novel inhibitor of neutrophil adhesion to coronary artery endothelial cells injured by calcineurin inhibition. Circulation. 2011;124(11 suppl):S197-S203.
36. Xu D, Perez RE, Ekekezie II, Navarro A, Truog WE. Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death. Am J Physiol Lung Cell Mol Physiol. 2008;294(1):L17-L23. (Pubitemid 351380314)
37. Prince LS. Hyperoxia and EGFL7: saving cells from too much of a good thing. Am J Physiol Lung Cell Mol Physiol. 2008;294(1):L15-L16. (Pubitemid 351380313)
38. Liu H, Kennard S, Lilly B. NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. Circ Res. 2009;104(4):466-475.
39. Benedito R, Roca C, Sorensen I, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell. 2009;137(6):1124-1135.
40. Hellstrom M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007; 445(7129):776-780. (Pubitemid 46279716)
41. Lobov IB, Renard RA, Papadopoulos N, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A. 2007;104(9):3219-3224. (Pubitemid 46364140)
42. Suchting S, Freitas C, le Noble F, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A. 2007;104(9):3225-3230. (Pubitemid 46364141)
43. Henderson AM, Wang SJ, Taylor AC, Aitkenhead M, Hughes CC. The basic helix-loophelix transcription factor HESR1 regulates endothelial cell tube formation. J Biol Chem. 2001; 276(9):6169-6176.
44. Noseda M, Chang L, McLean G, et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol. 2004;24(20):8813-8822. (Pubitemid 39313888)
45. Sainson RC, Aoto J, Nakatsu MN, et al. Cellautonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J. 2005;19(8):1027-1029. (Pubitemid 40827740)
46. Taylor KL, Henderson AM, Hughes CCW. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/ KDR expression. Microvasc Res. 2002;64(3): 372-383. (Pubitemid 35370739)
47. Trindade A, Kumar SR, Scehnet JS, et al. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood. 2008;112(5):1720-1729.
48. Uyttendaele H, Ho J, Rossant J, Kitajewski J. Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci U S A. 2001;98(10): 5643-5648. (Pubitemid 32435695)
49. Diaz R, Silva J, Garcia JM, et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer. 2008;47(9):794-802.
50. Huang CH, Li XJ, Zhou YZ, Luo Y, Li C, Yuan XR. Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol. 2010;136(11):1737-1743.
51. Wu F, Yang LY, Li YF, Ou DP, Chen DP, Fan C. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology. 2009;50(6):1839-1850.
52. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.
53. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444(7122):1032-1037. (Pubitemid 46018516)
54. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444(7122):1083-1087. (Pubitemid 46018529)
55. Scehnet JS, Jiang W, Kumar SR, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 2007;109(11):4753-4760. (Pubitemid 46827768)
56. Funahashi Y, Hernandez SL, Das I, et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008;68(12):4727-4735.
57. Liu Z, Turkoz A, Jackson EN, et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest. 2011;121(2): 800-808.
58. Yan MH, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010;463(7282):E6-E7.
59. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009;335(1):261-269.
60. De Bock K, Cauwenberghs S, Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev. 2011;21(1):73-79.
61. Delfortrie S, Pinte S, Mattot V, et al. Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. Cancer Res. 2011; 71(23):7176-7186.